Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients

Table 1 Demographic and clinical characteristics of patients n (%)

Characteristic	Patients
Age
n	104
Mean (yr ± SD)	49.9 ± 10.5
Min, max (yr)	29.0, 78.0
Median (yr) (IQR)	51.5 (41.0, 58.2)
Gender
n	104
Female	46 (44.2)
Male	58 (55.8)
Ethnicity
n	104
Hispanic or Latino	48 (46.2)
Not Hispanic or Latino	56 (53.8)
Race
n	104
White	91 (87.5)
Black	11 (10.6)
Unknown	2 (2)
Current comorbidities
n	104
Hypertension	46 (44.2)
Obesity	35 (33.7)
Cirrhosis, Child-Pugh A	21 (20.2)
Hepatic steatosis	18 (17.3)
Diabetes mellitus, type II	17(16.3)
Hyperlipidemia	17 (16.3)
Chronic kidney disease	3 (3)
Coronary artery disease	3 (3)
Atherosclerosis	1 (1)
Congestive heart failure	1 (1)
HIV	1 (1)
Genotype
n	100
GT1a	86 (86)
GT1b	14 (14)
Prior HCV treatment
n	100
IFN	2 (2)
IFN+RBV	3 (3)
PegIFN	1 (1)
PegIFN+RBV	10 (10)

SD: Standard deviation; IQR: Interquartile range; GT1: Genotype 1; IFN: Interferon; PegIFN: Pegylated interferon; RBV: Ribavirin.